The study aims to investigate the efficacy of favipiravir in high-risk COVID-19 patients. The
study population includes symptomatic mild-to-moderate COVID-19 inpatients, within first 7
days of illness, who are 50 years old and above, and have 1 or more comorbidities. The study
is designed as a randomised, open-label, multicenter clinical trial where the patients are
randomised 1:1 to groups receiving favipiravir (5 days) versus no favipiravir.
Phase:
Phase 3
Details
Lead Sponsor:
Penang Hospital, Malaysia
Collaborators:
Enche' Besar Hajjah Khalsom Hospital Institute for Clinical Research Jasin Hospital Kepala Batas Hospital Melaka Hospital Permai Hospital Raja Perempuan Zainab II Hospital Raja Permaisuri Bainun Hospital Sultanah Aminah Hospital Sultanah Nur Zahirah Hospital Sungai Buloh Hospital Tampin Hospital Tengku Ampuan Afzan Hospital The Queen Elizabeth Hospital Tuanku Fauziah Hospital Tuanku Jaafar Hospital Tumpat Hospital